Jeff Yass’s Foghorn Therapeutics FHTX Stock Holding History

Jeff Yass’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,400	Closed	-$189K	–	13198
2022 Q1	$189K	Sell	12,400 -28,300	-70%	-$388K	﹤0.01%	11301
2021 Q4	$931K	Buy	+40,700	New	+$585K	﹤0.01%	7491

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Jeff Yass's FHTX Position: Q2 2026 in Review

Jeff Yass sold out of Foghorn Therapeutics (FHTX) in Q2 2026, closing a stake of 11,637 shares — an estimated $55.6K sold.

Jeff Yass first reported a position in FHTX in Q4 2020 and held it in 11 quarters. The position peaked at $566K in Q4 2020. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

Jeff Yass reported no remaining Foghorn Therapeutics position as of Q2 2026 after selling out during the quarter.
Jeff Yass sold 11,637 Foghorn Therapeutics shares in Q2 2026, an estimated $55.6K.
Jeff Yass first reported a position in Foghorn Therapeutics in Q4 2020 and held it in 11 quarters.
Jeff Yass's Foghorn Therapeutics position peaked at $566K in Q4 2020.
102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.